Latest AKT Stories
-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor- SEATTLE, Dec. 9, 2014 /PRNewswire/ -- CTI BioPharma Corp.
Max Muscle has just released one of its newest products and it uses patented technology to deliver muscle packing results. Salt Lake City, UT (PRWEB) December
Max Muscle South Metro is one of the franchises most successful stores, and they are now carrying Maxxtor. Highlands Ranch, CO (PRWEB) November 03, 2014
Max Muscle South Metro has taken a new angle by hiring only the most qualified people and delivering new science driven products.
NEW YORK, Sept.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells.
- A trick or prank.